sorafenib increases 18-fdg colic uptake demonstration in patients with differentiated thyroid cancer索拉非尼增加18-fdg绞痛吸收示范分化型甲状腺癌患者.pdf
文本预览下载声明
Ciappuccini et al. EJNMMI Research 2012, 2:18
/content/2/1/18
SHORT COMMUNICATION Open Access
Sorafenib increases 18-FDG colic uptake:
demonstration in patients with differentiated
thyroid cancer
1* 2 3 4
Renaud Ciappuccini , Géraldine Trzepla , Natacha Heutte , Emmanuel Sevin ,
Marie Pierre Galais4 and Stéphane Bardet1
Abstract
Background: To assess 18-fluorodeoxyglucose (FDG) bowel uptake in patients with differentiated thyroid cancer
(DTC) treated with sorafenib.
Findings: Visual (5-point scale) and high maximum standard uptake value (SUVmax) semi-quantitative analyses
were conducted in 63 positron emission tomography (PET) studies performed in patients on sorafenib (group 1,
n = 20), in a control group (group 2, n = 28) and in patients on sunitinib or vandetanib (group 3, n = 15).
Moderate or high and diffuse bowel uptake (grade 4 or 5) was observed in 90% of the PET scans of group 1 versus
none in group 2. Only 20% of PET scans in group 3 were scored grade 4. SUVmax values were significantly higher
for all colic segments in group 1 than in group 2 (P 0.0001) or 3 (P 0.0004). This uptake pattern appeared rapidly
(one month) and disappeared after sorafenib withdrawal.
Conclusions: FDG uptake is increased in the colon of DTC patients treated by sorafenib.
Keywords: Sorafenib, FDG PET, Thyroid cancer, Colic uptake
Findings patients treated by other TKI such as sunitinib and
Background vandetanib.
Sorafenib is a new targeted therapy with an angiogenesis
inhibiting activity, belonging to the tyrosine kinase inhi- Methods
bitors (TKI) family [1]. This multikinase inhibi
显示全部